Comparison of pulmonary function test, diffusion capacity, blood gas analysis and CT scan in patients with and without persistent respiratory symptoms following COVID-19.
Diffusion capacity
Long COVID
SARS-CoV2
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
16 May 2022
16 May 2022
Historique:
received:
17
08
2021
accepted:
03
05
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
19
5
2022
Statut:
epublish
Résumé
Long-lasting symptoms following SARS-CoV2-infection have been described in several studies. However, there is only limited knowledge about the ongoing pathophysiology and the association with pathological findings in medical examinations. In this post hoc analysis of a prospective trial, 135 patients following COVID-19 were enrolled and grouped with respect to the presence or absence of respiratory ongoing symptoms following COVID-19. Pulmonary function test (PFT), diffusion capacity measurement (TLCO SB and TLCO/VA), blood gas analysis (BGA), laboratory tests and high-resolution computed tomography (HRCT) of patients with persistent respiratory symptoms were compared to those of asymptomatic patients. In this analysis, 71% (96/135) of all patients (mean age 49 years; range 20-91 years) reported long-lasting symptoms after a median (IQR) of 85 days (60-116) following COVID-19 whereby 57.8% (78/135) complained about persistent pulmonary symptoms. Pathological findings in blood test, PFT, TLCO, BGA and/or HRCT were found in 71.8% and 64.1% of patients with and without long-lasting respiratory symptoms respectively. Patients with persistent respiratory symptoms were significantly younger and presented a significant lower FVC (%), TLC (L), and TLCO SB compared to asymptomatic patients (p < 0.05). The multiple logistic regression results in a significant effect of age (p = 0.004) and TLCO SB (p = 0.042). Following COVID-19, a large proportion of patients experience ongoing symptoms, whereby the respiratory symptoms are the predominant complaints. Compared to asymptomatic patients, patients with ongoing symptoms were younger and presented a significant lower FVC, TLC and TLCO SB. The multiple logistic regression demonstrated only a significant association between the TLCO SB as the only PFT parameter and the perceived symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Long-lasting symptoms following SARS-CoV2-infection have been described in several studies. However, there is only limited knowledge about the ongoing pathophysiology and the association with pathological findings in medical examinations.
METHODS
METHODS
In this post hoc analysis of a prospective trial, 135 patients following COVID-19 were enrolled and grouped with respect to the presence or absence of respiratory ongoing symptoms following COVID-19. Pulmonary function test (PFT), diffusion capacity measurement (TLCO SB and TLCO/VA), blood gas analysis (BGA), laboratory tests and high-resolution computed tomography (HRCT) of patients with persistent respiratory symptoms were compared to those of asymptomatic patients.
RESULTS
RESULTS
In this analysis, 71% (96/135) of all patients (mean age 49 years; range 20-91 years) reported long-lasting symptoms after a median (IQR) of 85 days (60-116) following COVID-19 whereby 57.8% (78/135) complained about persistent pulmonary symptoms. Pathological findings in blood test, PFT, TLCO, BGA and/or HRCT were found in 71.8% and 64.1% of patients with and without long-lasting respiratory symptoms respectively. Patients with persistent respiratory symptoms were significantly younger and presented a significant lower FVC (%), TLC (L), and TLCO SB compared to asymptomatic patients (p < 0.05). The multiple logistic regression results in a significant effect of age (p = 0.004) and TLCO SB (p = 0.042).
CONCLUSION
CONCLUSIONS
Following COVID-19, a large proportion of patients experience ongoing symptoms, whereby the respiratory symptoms are the predominant complaints. Compared to asymptomatic patients, patients with ongoing symptoms were younger and presented a significant lower FVC, TLC and TLCO SB. The multiple logistic regression demonstrated only a significant association between the TLCO SB as the only PFT parameter and the perceived symptoms.
Identifiants
pubmed: 35578190
doi: 10.1186/s12890-022-01987-z
pii: 10.1186/s12890-022-01987-z
pmc: PMC9109200
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Informations de copyright
© 2022. The Author(s).
Références
Clin Microbiol Infect. 2022 Jul;28(7):955-972
pubmed: 35182760
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Respir Physiol Neurobiol. 2021 Jun;288:103644
pubmed: 33647535
EClinicalMedicine. 2020 Aug;25:100463
pubmed: 32838236
Nature. 2020 Nov;587(7834):466-471
pubmed: 33116313
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Respir Res. 2020 Jun 29;21(1):163
pubmed: 32600344
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
BMJ. 2021 Jan 22;372:n136
pubmed: 33483331
J Clin Med. 2021 Dec 16;10(24):
pubmed: 34945213
Clin Microbiol Infect. 2021 Oct;27(10):1507-1513
pubmed: 34111579
Eur J Intern Med. 2021 Oct;92:55-70
pubmed: 34167876
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
EClinicalMedicine. 2021 Sep;39:101079
pubmed: 34405138
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953